Verrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma.
President and Chief Executive Officer Jayson Rieger said the company saw “accelerating growth in market demand for YCANTH,” with record dispensed applicator units during the quarter and in March. He added that preliminary April results showed dispensed applicator units increased again from March’s record level.
